Bempedoic acid Clinical Trials (2026): 43 Studies for Hypercholesterolemia & Mixed Dyslipidemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
43 Bempedoic acid clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 25 indications (including Hypercholesterolemia & Mixed Dyslipidemia) and 33,928 total planned enrollment. 13 Phase 3 Bempedoic acid trials and 7 Phase 2, 6 Phase 4 are listed. 14 Bempedoic acid clinical trials are actively recruiting at 4 U.S. sites across 3 states. Most recent activity: NCT05103254 (May 2032).
Where to Participate: All Bempedoic acid Trial Sites in the U.S. (4 sites across 3 states)
Every actively recruiting Bempedoic acidtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | UCLA Center for Clinical AIDS Research and Education (CARE) | Los Angeles90095 | NCT05488431 | Map |
| CA | San Francisco General Hospital | San Francisco94110 | NCT05488431 | Map |
| NC | Evidera, PPD business unit | Morrisville27560 | NCT05103254 | Map |
| TX | UT Health Houston | Houston77030 | NCT05488431 | Map |
Bempedoic acid clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|
| P1 | 7 | 7 | |||||
| P2 | 1 | 5 | 1 | 7 | |||
| P3 | 2 | 9 | 2 | 13 | |||
| P4 | 2 | 2 | 2 | 6 | |||
| N/A | 4 | 2 | 1 | 1 | 2 | 10 |
Recruiting Bempedoic acid clinical trials (14)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05103254 | Bempedoic Acid Pregnancy Surveillance Program | — | Pregnancy | 20 | Sep 2021 |
| NCT07282821 | BEAT-PKDBempedoic Acid Therapy for Polycystic Kidney Disease | P2 | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | 120 | Jul 2026 |
| NCT07374861 | BEMPENETMulticenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy | — | Hypercholesterolemia | 1,500 | Nov 2025 |
| NCT07474649 | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events | P3 | Coronary Atherosclerosis | 103 | Jun 2026 |
| NCT05488431 | Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) | P2 | Dyslipidemias | 121 | Mar 2023 |
| NCT06686615 | TRICONOSA Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | — | Primary Hypercholesterolemiia | 2,000 | Feb 2025 |
| NCT07239414 | BASISBempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability | P3 | Cardiovascular | 690 | Nov 2025 |
| NCT07614958 | MEDICIPhase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days | P3 | Mixed Dyslipidemia | 426 | May 2026 |
| NCT07256171 | COASTCOAST Study - Cholesterol Optimization After Stroke | — | Stroke (CVA) or Transient Ischemic Attack | 500 | Jan 2026 |
| NCT05587621 | GoTIntensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) | N/A | ST Elevation Myocardial Infarction | 300 | Apr 2024 |
| NCT07508254 | TLD-ACSTriple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome | P4 | Acute Coronary Syndromes (ACS) | 120 | May 2026 |
| NCT07255820 | Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol | P4 | Type 2 Diabetes Mellitus | 126 | Jan 2026 |
| NCT06780410 | A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | P3 | Primary Hyperlipidemia | 240 | Dec 2024 |
| NCT06035874 | B-LIFTEffect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes | N/A | Type 2 Diabetes | 100 | Oct 2023 |
Bempedoic acid clinical trials by indication
Hypercholesterolemia (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07374861 | BEMPENET | N/A | recruiting | Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy |
| NCT04579367 | MILOS | N/A | active not recruiting | Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
| NCT05694260 | CLEAR Path 1 | P2 | completed | A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) |
| NCT06450366 | — | P3 | completed | A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) |
| NCT05546398 | — | N/A | completed | SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® |
| NCT04784442 | — | P2 | completed | A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia |
| NCT03067441 | — | P3 | completed | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) |
| NCT02991118 | CLEAR Wisdom | P3 | completed | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk |
| + 4 more, see All trials below. | ||||
Healthy Subjects (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07268625 | — | P1 | completed | Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin |
| NCT07235189 | — | P1 | completed | A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin |
| NCT07201545 | — | P1 | completed | Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin |
| NCT07182383 | — | P1 | completed | Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin |
Hypercholesterolaemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07170852 | — | P1 | completed | Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets |
| NCT06923956 | — | P1 | completed | Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions. |
Dyslipidemias (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05488431 | — | P2 | recruiting | Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) |
| NCT06381947 | BESAFE | P4 | unknown | Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients |
Hyper-low-density Lipoprotein (LDL) Cholesterolemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05687071 | — | P3 | completed | A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia |
| NCT05683340 | — | P3 | completed | A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia |
Cardiovascular Diseases (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05263778 | — | P4 | unknown | Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study |
| NCT02993406 | CLEAR Outcomes | P3 | completed | Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
ADPKD (Autosomal Dominant Polycystic Kidney Disease) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07282821 | BEAT-PKD | P2 | not yet recruiting | Bempedoic Acid Therapy for Polycystic Kidney Disease |
Coronary Atherosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07474649 | — | P3 | not yet recruiting | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events |
Mixed Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07614958 | MEDICI | P3 | recruiting | Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days |
Acute Coronary Syndromes (ACS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07508254 | TLD-ACS | P4 | not yet recruiting | Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome |
Primary Hypercholesterolaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07206472 | Musashi | N/A | active not recruiting | A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia |
Stroke (CVA) or Transient Ischemic Attack (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07256171 | COAST | N/A | not yet recruiting | COAST Study - Cholesterol Optimization After Stroke |
Type 2 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07255820 | — | P4 | not yet recruiting | Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol |
Cardiovascular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07239414 | BASIS | P3 | not yet recruiting | Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability |
Primary Hypercholesterolemia or Mixed Hyperlipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06925100 | CLEAR Taiwan | P4 | completed | A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan |
Primary Hypercholesterolemiia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06686615 | TRICONOS | N/A | recruiting | A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia |
Primary Hyperlipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06780410 | — | P3 | recruiting | A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid |
Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06742853 | — | P1 | completed | A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. |
ST Elevation Myocardial Infarction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05587621 | GoT | N/A | not yet recruiting | Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) |
Type 2 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06035874 | B-LIFT | N/A | recruiting | Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes |
Primary Hypercholesterolemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05798390 | MILOS-Spain | N/A | withdrawn | Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia |
Healthy Lactating Women (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06021951 | FCDP | P4 | completed | Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women |
Pregnancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05103254 | — | N/A | recruiting | Bempedoic Acid Pregnancy Surveillance Program |
Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03531905 | FDC | P2 | completed | Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C |
Hyperlipidemias (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03337308 | — | P3 | completed | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy |
Bempedoic acid pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| TLD-ACS | NCT07508254 | P4 | not yet recruiting | Acute Coronary Syndromes (ACS) | 120 | PMID 41200807 |
| CLEAR Taiwan | NCT06925100 | P4 | completed | Primary Hypercholesterolemia or Mixed Hyperlipidemia | 180 | PMID 42134976 |
| BESAFE | NCT06381947 | P4 | unknown | Dyslipidemias | 130 | PMID 25825402 |
| FCDP | NCT06021951 | P4 | completed | Healthy Lactating Women | 16 | — |
| BASIS | NCT07239414 | P3 | not yet recruiting | Cardiovascular | 690 | — |
| MEDICI | NCT07614958 | P3 | recruiting | Mixed Dyslipidemia | 426 | — |
| CLEAR Outcomes | NCT02993406 | P3 | completed | Cardiovascular Diseases | 13,970 | PMID 42201706 |
| CLEAR Wisdom | NCT02991118 | P3 | completed | Hypercholesterolemia | 779 | PMID 35916348 |
| CLEAR Serenity | NCT02988115 | P3 | completed | Hypercholesterolemia | 345 | PMID 30922146 |
| ETC-1002 | NCT03001076 | P3 | completed | Hypercholesterolemia | 269 | PMID 29910030 |
| BEAT-PKD | NCT07282821 | P2 | not yet recruiting | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | 120 | PMID 36504724 |
| CLEAR Path 1 | NCT05694260 | P2 | completed | Hypercholesterolemia | 31 | — |
| FDC | NCT03531905 | P2 | completed | Diabetes | 242 | PMID 24385236 |
| ETC-1002 | NCT03193047 | P2 | completed | Hypercholesterolemia | 59 | PMID 12672737 |
| ETC-1002 | NCT03051100 | P2 | completed | Hypercholesterolemia | 63 | PMID 26073387 |
Terminated and withdrawn Bempedoic acid trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05798390withdrawnTreatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
All Bempedoic acid trials (43)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05103254 | Bempedoic Acid Pregnancy Surveillance Program | — | recruiting | 20 | Esperion Therapeutics, Inc. | Sep 2021 | |
| NCT07282821 | BEAT-PKD | Bempedoic Acid Therapy for Polycystic Kidney Disease | P2 | not yet recruiting | 120 | Kenneth Hallows | Jul 2026 |
| NCT07206472 | Musashi | A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia | — | active not recruiting | 2,560 | Daiichi Sankyo | Mar 2026 |
| NCT07374861 | BEMPENET | Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy | — | recruiting | 1,500 | Federico II University | Nov 2025 |
| NCT07474649 | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events | P3 | not yet recruiting | 103 | Daiichi Sankyo | Jun 2026 | |
| NCT05488431 | Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) | P2 | recruiting | 121 | Priscilla Hsue, MD | Mar 2023 | |
| NCT06686615 | TRICONOS | A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | — | recruiting | 2,000 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Feb 2025 |
| NCT07239414 | BASIS | Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability | P3 | not yet recruiting | 690 | Sohaib Ashraf | Nov 2025 |
| NCT07614958 | MEDICI | Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days | P3 | recruiting | 426 | A. Menarini International Licensing S.A. | May 2026 |
| NCT07256171 | COAST | COAST Study - Cholesterol Optimization After Stroke | — | not yet recruiting | 500 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Jan 2026 |
| NCT05587621 | GoT | Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) | N/A | not yet recruiting | 300 | Jena University Hospital | Apr 2024 |
| NCT07508254 | TLD-ACS | Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome | P4 | not yet recruiting | 120 | Punjab Institute of Cardology | May 2026 |
| NCT04579367 | MILOS | Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | — | active not recruiting | 5,000 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Jan 2021 |
| NCT07255820 | Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol | P4 | not yet recruiting | 126 | Bahria University | Jan 2026 | |
| NCT05798390 | MILOS-Spain | Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia | — | withdrawn | 0 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Sep 2023 |
| NCT07268625 | Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin | P1 | completed | 58 | Daiichi Sankyo | Dec 2025 | |
| NCT07235189 | A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin | P1 | completed | 58 | Daiichi Sankyo | Oct 2025 | |
| NCT07201545 | Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin | P1 | completed | 58 | Daiichi Sankyo | Oct 2025 | |
| NCT07182383 | Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin | P1 | completed | 58 | Daiichi Sankyo | Sep 2025 | |
| NCT06780410 | A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | P3 | recruiting | 240 | Gan & Lee Pharmaceuticals. | Dec 2024 | |
| NCT06742853 | A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. | P1 | completed | 81 | AstraZeneca | Dec 2024 | |
| NCT06925100 | CLEAR Taiwan | A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan | P4 | completed | 180 | Daiichi Sankyo | Apr 2025 |
| NCT06035874 | B-LIFT | Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes | N/A | recruiting | 100 | Medanta, The Medicity, India | Oct 2023 |
| NCT07170852 | Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets | P1 | completed | 32 | Humanis Saglık Anonim Sirketi | May 2025 | |
| NCT06381947 | BESAFE | Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients | P4 | unknown | 130 | University of Salerno | May 2024 |
| NCT05694260 | CLEAR Path 1 | A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) | P2 | completed | 31 | Esperion Therapeutics, Inc. | Jan 2023 |
| NCT06450366 | A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) | P3 | completed | 301 | Merck Sharp & Dohme LLC | Jul 2024 | |
| NCT06923956 | Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions. | P1 | completed | 14 | Humanis Saglık Anonim Sirketi | Dec 2024 | |
| NCT05687071 | A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | P3 | completed | 130 | Otsuka Pharmaceutical Co., Ltd. | Feb 2023 | |
| NCT06021951 | FCDP | Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women | P4 | completed | 16 | Esperion Therapeutics, Inc. | Aug 2023 |
| NCT05683340 | A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | P3 | completed | 96 | Otsuka Pharmaceutical Co., Ltd. | Feb 2023 | |
| NCT05263778 | Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study | P4 | unknown | 500 | Kaiser Permanente | Mar 2022 | |
| NCT05546398 | SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® | — | completed | 500 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Apr 2022 | |
| NCT02993406 | CLEAR Outcomes | Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo | P3 | completed | 13,970 | Esperion Therapeutics, Inc. | Dec 2016 |
| NCT04784442 | A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia | P2 | completed | 188 | Otsuka Pharmaceutical Co., Ltd. | Mar 2021 | |
| NCT03067441 | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) | P3 | completed | 1,462 | Esperion Therapeutics, Inc. | Feb 2017 | |
| NCT03531905 | FDC | Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C | P2 | completed | 242 | Esperion Therapeutics, Inc. | May 2018 |
| NCT02991118 | CLEAR Wisdom | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk | P3 | completed | 779 | Esperion Therapeutics, Inc. | Nov 2016 |
| NCT03337308 | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy | P3 | completed | 382 | Esperion Therapeutics, Inc. | Oct 2017 | |
| NCT02988115 | CLEAR Serenity | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant | P3 | completed | 345 | Esperion Therapeutics, Inc. | Nov 2016 |
| NCT03193047 | ETC-1002 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy | P2 | completed | 59 | Esperion Therapeutics, Inc. | Apr 2017 |
| NCT03001076 | ETC-1002 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) | P3 | completed | 269 | Esperion Therapeutics, Inc. | Nov 2016 |
| NCT03051100 | ETC-1002 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C | P2 | completed | 63 | Esperion Therapeutics, Inc. | Jan 2017 |
Bempedoic acid clinical trials: frequently asked questions
- How many Bempedoic acid clinical trials are there?
- 43 Bempedoic acid clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 24 are marked completed.
- Are Bempedoic acid clinical trials recruiting in 2026?
- Yes — 7 Bempedoic acid trials are actively recruiting in 2026, with 4 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Bempedoic acid being studied for?
- Bempedoic acid is being studied for Hypercholesterolemia, Mixed Dyslipidemia, Cardiovascular Diseases, Healthy Subjects, Statin Adverse Reaction and 35 more. The trials are grouped by indication on this page.
- What phase is Bempedoic acid in?
- Bempedoic acid clinical trials span 6 Phase 4, 13 Phase 3, 7 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Bempedoic acid clinical trials?
- The lead sponsor across the most Bempedoic acid trials is Esperion Therapeutics, Inc., with 19 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Bempedoic acidas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: